PDEs create local domains of cAMP signaling

Journal of Molecular and Cellular Cardiology

Volumn 52, Issue 2, 2012, Pages 323-329

  Mika, Delphine ^a,b   Leroy, JérÔme ^a,b   Vandecasteele, Grégoire ^a,b   Fischmeister, Rodolphe ^a,b  

^a Universite Paris Sud   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Compartmentation; Cyclic AMP; Heart; Hormonal regulation; Phosphodiesterases

Indexed keywords

CALCIUM ION; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; SPLEEN EXONUCLEASE;

AMINO TERMINAL SEQUENCE; CALCIUM TRANSPORT; CELL MEMBRANE; CYTOPLASM; DIFFUSION; DISEASE MODEL; ENZYME PHOSPHORYLATION; HEART FAILURE; HEART HYPERTROPHY; HEART MUSCLE CELL; HUMAN; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; SARCOPLASMIC RETICULUM; SIGNAL TRANSDUCTION;

ANIMALS; CYCLIC AMP; HEART FAILURE; HUMANS; ISOENZYMES; MYOCYTES, CARDIAC; PHOSPHORIC DIESTER HYDROLASES; SIGNAL TRANSDUCTION;

EID: 84855989070     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2011.08.016     Document Type: Review

References (137)

1. Tasken K., Aandahl E.M. Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol Rev 2004, 84:137-167.
2. Fischmeister R., Castro L.R.V., Abi-Gerges A., Rochais F., Jurevičius J., Leroy J., et al. Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases. Circ Res 2006, 99:816-828.
3. Bers D.M. Cardiac excitation-contraction coupling. Nature 2002, 415:198-205.
4. de Rooij J., Zwartkruis F.J., Verheijen M.H., Cool R.H., Nijman S.M., Wittinghofer A., et al. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 1998, 396:474-477.
5. Morel E., Marcantoni A., Gastineau M., Birkedal R., Rochais F., Garnier A., Lompré A.-M., Vandecasteele G., Lezoualc'h F. The cAMP-binding protein Epac induces cardiomyocyte hypertrophy. Circ Res 2005, 97:1296-1304.
6. Métrich M., Lucas A., Gastineau M., Samuel J.-L., Heymes C., Morel E., Lezoualc'h F. Exchange protein activated by cAMP (Epac) mediates ß-adrenergic receptor-induced cardiomyocyte hypertrophy. Circ Res 2008, 102:959-965.
7. Barbuti A., DiFrancesco D. Control of cardiac rate by "funny" channels in health and disease. Ann N Y Acad Sci 2008, 1123:213-223.
8. Steinberg S.F., Brunton L.L. Compartmentation of G protein-coupled signaling pathways in cardiac myocytes. Annu Rev Pharmacol Toxicol 2001, 41:751-773.
9. Corbin J.D., Keely S.L. Characterization and regulation of heart adenosine 3':5'-monophosphate-dependent protein kinase isozymes. J Biol Chem 1977, 252:910-918.
10. Keely S.L. Prostaglandin E1 activation of heart cAMP-dependent protein kinase: apparent dissociation of protein kinase activation from increases in phosphorylase activity and contractile force. Mol Pharmacol 1979, 15:235-245.
11. Corbin J.D., Sugden P.H., Lincoln T.M., Keely S.L. Compartmentalization of adenosine 3':5'-monophosphate and adenosine 3':5'-monophosphate-dependent protein kinase in heart tissue. J Biol Chem 1977, 252:3854-3861.
12. Buxton I.L.O., Brunton L.L. Compartments of cyclic AMP and protein kinase in mammalian cardiomyocytes. J Biol Chem 1983, 258:10233-10239.
13. Hayes J.S., Brunton L.L., Mayer S.E. Selective activation of particulate cAMP-dependent protein kinase by isoproterenol and prostaglandin E1. J Biol Chem 1980, 255:5113-5119.
14. Brunton L.L., Hayes J.S., Mayer S.E. Hormonally specific phosphorylation of cardiac troponin I and activation of glycogen phosphorylase. Nature 1979, 280:78-80.
15. Hayes J.S., Brunton L.L., Brown J.H., Reese J.B., Mayer S.E. Hormonally specific expression of cardiac protein kinase activity. Proc Natl Acad Sci U S A 1979, 76:1570-1574.
16. 2+ current in single rat ventricular cells. Circ Res 1993, 73:286-300.
17. 2+ dynamics, contractility, or phospholamban phosphorylation. J Biol Chem 1994, 269:19151-19156.
18. Calaghan S., Kozera L., White E. Compartmentalisation of cAMP-dependent signalling by caveolae in the adult cardiac myocyte. J Mol Cell Cardiol 2008, 45:88-92.
19. Altschuld R.A., Starling R.C., Hamlin R.L., Billman G.E., Hensley J., Castillo L., et al. Response of failing canine and human heart cells to beta(2)-adrenergic stimulation. Circulation 1995, 92:1612-1618.
20. 2-Adrenergic cAMP signaling is uncoupled from phosphorylation of cytoplasmic proteins in canine heart. Circulation 1999, 99:2458-2465.
21. 2-adrenoceptor signaling in the adult rat heart. Cardiovasc Res 2003, 57:694-703.
22. Farah A.E. Glucagon and the heart. Exp Pharmacol 1983, 53:553-609.
23. Juan-Fita M.J., Vargas M.L., Kaumann A.J., Hernandez Cascales J. Rolipram reduces the inotropic tachyphylaxis of glucagon in rat ventricular myocardium. Naunyn Schmiedebergs Arch Pharmacol 2004, 370:324-329.
24. Vila Petroff M.G., Egan J.M., Wang X., Sollott S.J. Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes. Circ Res 2001, 89:445-452.
25. s-coupled receptors in adult rat ventricular myocytes. Circ Res 2006, 98:1081-1088.
26. 2+ channel regulation in guinea-pig ventricular myocytes. J Physiol 2007, 580:765-776.
27. Di Benedetto G., Zoccarato A., Lissandron V., Terrin A., Li X., Houslay M.D., et al. Protein kinase A type I and type II define distinct intracellular signaling compartments. Circ Res 2008, 103:836-844.
28. Agarwal S.R., MacDougall D.A., Tyser R., Pugh S.D., Calaghan S.C., Harvey R.D. Effects of cholesterol depletion on compartmentalized cAMP responses in adult cardiac myocytes. J Mol Cell Cardiol 2011, 50:500-509.
29. Brette F., Orchard C. T-tubule function in mammalian cardiac myocytes. Circ Res 2003, 92:1182-1192.
30. Gao T.Y., Puri T.S., Gerhardstein B.L., Chien A.J., Green R.D., Hosey M.M. Identification and subcellular localization of the subunits of L-type calcium channels and adenylyl cyclase in cardiac myocytes. J Biol Chem 1997, 272:19401-19407.
31. v1.2 channels via a leucine zipper interaction with A kinase-anchoring protein 15. Proc Natl Acad Sci U S A 2003, 100:13093-13098.
32. 2+ exchange activity is localized in the T-tubules of rat ventricular myocytes. Circ Res 2002, 91:315-322.
33. Despa S., Brette F., Orchard C.H., Bers D.M. Na/Ca exchange and Na/K-ATPase function are equally concentrated in transverse tubules of rat ventricular myocytes. Biophys J 2003, 85:3388-3396.
34. Chase A., Orchard C.H. Ca efflux via the sarcolemmal Ca ATPase occurs only in the T-tubules of rat ventricular myocytes. J Mol Cell Cardiol 2011, 50:187-193.
35. s and adenylyl cyclase in transverse tubules of heart: implications for cAMP-dependent signaling. Am J Physiol Heart Circ Physiol 1999, 277:H1841-H1848.
36. Lugnier C., Muller B., Lebec A., Beaudry C., Rousseau E. Characterization of indolidan-sensitive and rolipram-sensitive cyclic nucleotide phosphodiesterases in canine and human cardiac microsomal fractions. J Pharmacol Exp Ther 1993, 265:1142-1151.
37. Mongillo M., McSorley T., Evellin S., Sood A., Lissandron V., Terrin A., et al. Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ Res 2004, 95:65-75.
38. Yang J.C., Drazba J.A., Ferguson D.G., Bond M. A-kinase anchoring protein 100 (AKAP100) is localized in multiple subcellular compartments in the adult rat heart. J Cell Biol 1998, 142:511-522.
39. 2-Adrenergic receptor redistribution in heart failure changes cAMP compartmentation. Science 2010, 327:1653-1657.
40. Ostrom R.S., Gregorian C., Drenan R.M., Xiang Y., Regan J.W., Insel P.A. Receptor number and caveolar co-localization determine receptor coupling efficiency to adenylyl cyclase. J Biol Chem 2001, 276:42063-42069.
41. Scott J.D., Santana L.F. A-kinase anchoring proteins: getting to the heart of the matter. Circulation 2010, 121:1264-1271.
42. Marx S.O., Reiken S., Hisamatsu Y., Jayaraman T., Burkhoff D., Rosemblit N., et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (Ryanodine receptor): defective regulation in failing hearts. Cell 2000, 101:365-376.
43. Marx S.O., Kurokawa J., Reiken S., Motoike H., D'Armiento J., Marks A.R., et al. Requirement of a macromolecular signaling complex for β adrenergic receptor modulation of the KCNQ1-KCNE1 potassium channel. Science 2002, 295:496-499.
44. Dodge-Kafka K.L., Soughayer J., Pare G.C., Carlisle Michel J.J., Langeberg L.K., Kapiloff M.S., Scott J.D. The protein kinase A anchoring protein mAKAP co-ordinates two integrated cAMP effector pathways. Nature 2005, 437:574-578.
45. Bauman A.L., Soughayer J., Nguyen B.T., Willoughby D., Carnegie G.K., Wong W., et al. Dynamic regulation of cAMP synthesis through anchored PKA-adenylyl cyclase V/VI complexes. Mol Cell 2006, 23:925-931.
46. Dodge K.L., Khouangsathiene S., Kapiloff M.S., Mouton R., Hill E.V., Houslay M.D., et al. mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module. EMBO J 2001, 20:1921-1930.
47. Ks potassium channel macromolecular complex includes the phosphodiesterase PDE4D3. J Biol Chem 2009, 284:9140-9146.
48. Rich T.C., Fagan K.A., Nakata H., Schaack J., Cooper D.M.F., Karpen J.W. Cyclic nucleotide-gated channels colocalize with adenylyl cyclase in regions of restricted cAMP diffusion. J Gen Physiol 2000, 116:147-161.
49. Saucerman J.J., Zhang J., Martin J.C., Peng L.X., Stenbit A.E., Tsien R.Y., et al. Systems analysis of PKA-mediated phosphorylation gradients in live cardiac myocytes. Proc Natl Acad Sci U S A 2006, 103:12923-12928.
50. Beavo J.A., Francis S.H., Houslay M.D. Cyclic nucleotide phosphodiesterases in health and disease 2007, 1-713. CRC Press, Taylor & Francis Group, Boca Raton, Florida, USA.
51. Conti M., Beavo J.A. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 2007, 76:481-511.
52. Osadchii O.E. Myocardial phosphodiesterases and regulation of cardiac contractility in health and cardiac disease. Cardiovasc Drugs Ther 2007, 21:171-194.
53. Sonnenburg W.K., Mullaney P.J., Beavo J.A. Molecular cloning of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase cDNA-identification and distribution of isozyme variants. J Biol Chem 1991, 266:17655-17661.
54. Wechsler J., Choi Y.H., Krall J., Ahmad F., Manganiello V.C., Movsesian M.A. Isoforms of cyclic nucleotide phosphodiesterase PDE3A in cardiac myocytes. J Biol Chem 2002, 277:38072-38078.
55. Kostic M.M., Erdogan S., Rena G., Borchert G., Hoch B., Bartel S., et al. Altered expression of PDE1 and PDE4 cyclic nucleotide phosphodiesterase isoforms in 7-oxo-prostacyclin-preconditioned rat heart. J Mol Cell Cardiol 1997, 29:3135-3146.
56. Richter W., Jin S.L., Conti M. Splice variants of the cyclic nucleotide phosphodiesterase PDE4D are differentially expressed and regulated in rat tissue. Biochem J 2005, 388:803-811.
57. Abi-Gerges A., Richter W., Lefebvre F., Matéo P., Varin A., Heymes C., et al. Decreased expression and activity of cAMP phosphodiesterases in cardiac hypertrophy and its impact on ß-adrenergic cAMP signals. Circ Res 2009, 105:784-792.
58. Patrucco E., Albergine M.S., Santana L.F., Beavo J.A. Phosphodiesterase 8A (PDE8A) regulates excitation-contraction coupling in ventricular myocytes. J Mol Cell Cardiol 2010, 49:330-333.
59. Georget M., Mateo P., Vandecasteele G., Lipskaia L., Defer N., Hanoune J., et al. Cyclic AMP compartmentation due to increased cAMP-phosphodiesterase activity in transgenic mice with a cardiac-directed expression of the human adenylyl cyclase type 8 (AC8). FASEB J 2003, 17:1380-1391.
60. 2 adrenoceptor subtype-specific signaling in cardiac myocytes. Proc Natl Acad Sci U S A 2005, 102:909-914.
61. 2+ channel regulation in adult rat ventricular myocytes: role of phosphodiesterases. Circ Res 2008, 102:1091-1100.
62. Richter W., Xie M., Scheitrum C., Krall J., Movsesian M.A., Conti M. Conserved expression and functions of PDE4 in rodent and human heart. Basic Res Cardiol 2011, 106:249-262.
63. Sette C., Conti M. Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase-involvement of serine 54 in the enzyme activation. J Biol Chem 1996, 271:16526-16534.
64. Oki N., Takahashi S.I., Hidaka H., Conti M. Short term feedback regulation of cAMP in FRTL-5 thyroid cells. Role of PDE4D3 phosphodiesterase activation. J Biol Chem 2000, 275:10831-10837.
65. Rochais F., Vandecasteele G., Lefebvre F., Lugnier C., Lum H., Mazet J.-L., Cooper D.M.F., Fischmeister R. Negative feedback exerted by PKA and cAMP phosphodiesterase on subsarcolemmal cAMP signals in intact cardiac myocytes. An in vivo study using adenovirus-mediated expression of CNG channels. J Biol Chem 2004, 279:52095-52105.
66. Reeves M.L., Leigh B.K., England P.J. The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors. Biochem J 1987, 241:535-541.
67. Shahid M., Nicholson C.D. Comparison of cyclic nucleotide phosphodiesterase isoenzymes in rat and rabbit ventricular myocardium-positive inotropic and phosphodiesterase inhibitory effects of Org-30029, milrinone and rolipram. Naunyn Schmiedebergs Arch Pharmacol 1990, 342:698-705.
68. Masunaga R., Nagasaka A., Sawai Y., Hayakawa N., Nakai A., Hotta K., et al. Changes in cyclic nucleotide phosphodiesterase activity and calmodulin concentration in heart muscle of cardiomyopathic hamsters. J Mol Cell Cardiol 2004, 37:767-774.
69. Hambleton R., Krall J., Tikishvili E., Honeggar M., Ahmad F., Manganiello V.C., et al. Isoforms of cyclic nucleotide phosphodiesterase PDE3 and their contribution to cAMP-hydrolytic activity in subcellular fractions of human myocardium. J Biol Chem 2005, 280:39168-39174.
70. Vandeput F., Wolda S.L., Krall J., Hambleton R., Uher L., McCaw K.N., et al. Cyclic nucleotide phosphodiesterase PDE1C in human cardiac myocytes. J Biol Chem 2007, 282:32749-32757.
71. Rapundalo S.T., Solaro R.J., Kranias E.G. Inotropic responses to isoproterenol and phosphodiesterase inhibitors in intact guinea pig hearts: comparison of cyclic AMP levels and phosphorylation of sarcoplasmic reticulum and myofibrillar proteins. Circ Res 1989, 64:104-111.
72. Weishaar R.E., Kobylarz-Singer D.C., Steffen R.P., Kaplan H.R. Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility. Circ Res 1987, 61:539-547.
73. 2+ transients. Circ Res 1991, 69:1369-1379.
74. 2+ channels by ß-adrenergic agonists. Proc Natl Acad Sci U S A 1996, 93:295-299.
75. Zaccolo M., Pozzan T. Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes. Science 2002, 295:1711-1715.
76. Nikolaev V.O., Lohse M.J. Monitoring of cAMP synthesis and degradation in living cells. Physiology (Bethesda) 2006, 21:86-92.
77. 2+/calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy. Circ Res 2009, 105:956-964.
78. Simmons M.A., Hartzell H.C. Role of phosphodiesterase in regulation of calcium current in isolated cardiac myocytes. Mol Pharmacol 1988, 33:664-671.
79. Mongillo M., Tocchetti C.G., Terrin A., Lissandron V., Cheung Y.F., Dostmann W.R., et al. Compartmentalized phosphodiesterase-2 activity blunts ß-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway. Circ Res 2006, 98:226-234.
80. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 2006, 109:366-398.
81. 2+ current in single heart cells. Nature 1986, 323:273-275.
82. Hartzell H.C., Simmons M.A. Comparison of effects of acetylcholine on calcium and potassium currents in frog atrium and ventricle. J Physiol 1987, 389:411-422.
83. Méry P.-F., Pavoine C., Pecker F., Fischmeister R. Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic GMP-stimulated phosphodiesterase in isolated cardiac myocytes. Mol Pharmacol 1995, 48:121-130.
84. 2+ current to nitric oxide in frog ventricular myocytes. J Physiol 2001, 534:109-121.
85. Rivet-Bastide M., Vandecasteele G., Hatem S., Verde I., Benardeau A., Mercadier J.J., et al. cGMP-stimulated cyclic nucleotide phosphodiesterase regulates the basal calcium current in human atrial myocytes. J Clin Invest 1997, 99:2710-2718.
86. 2+ channel current in human atrial myocytes. J Physiol 2001, 533:329-340.
87. Castro L.R.V., Verde I., Cooper D.M.F., Fischmeister R. Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes. Circulation 2006, 113:2221-2228.
88. Castro L.R.V., Schittl J., Fischmeister R. Feedback control through cGMP-dependent protein kinase contributes to differential regulation and compartmentation of cGMP in rat cardiac myocytes. Circ Res 2010, 107:1232-1240.
89. Stangherlin A., Gesellchen F., Zoccarato A., Terrin A., Fields L.A., Berrera M., et al. cGMP signals modulate cAMP levels in a compartment-specific manner to regulate catecholamine-dependent signaling in cardiac myocytes. Circ Res 2011, 108:929-939.
90. Muller B., Stoclet J.-C., Lugnier C. Cytosolic and membrane-bound cyclic nucleotide phosphodiesterases from guinea pig cardiac ventricles. Eur J Pharmacol 1992, 225:263-272.
91. Kauffman R.F., Crowe V.G., Utterback B.G., Robertson D.W. LY195115: a potent, selective inhibitor of cyclic nucleotide phosphodiesterase located in the sarcoplasmic reticulum. Mol Pharmacol 1986, 30:609-616.
92. Kerfant B.G., Zhao D., Lorenzen-Schmidt I., Wilson L.S., Cai S., Chen S.R., et al. PI3KY is required for PDE4, not PDE3, activity in subcellular microdomains containing the sarcoplasmic reticular calcium ATPase in cardiomyocytes. Circ Res 2007, 101:400-408.
93. Weishaar R.E., Kobylarz-Singer D.C., Kaplan H.R. Subclasses of cyclic AMP phosphodiesterase in cardiac muscle. J Mol Cell Cardiol 1987, 19:1025-1036.
94. Bethke T., Eschenhagen T., Klimkiewicz A., Kohl C., von der Leyen H., Mehl H., et al. Phosphodiesterase inhibition by enoximone in preparations from nonfailing and failing human hearts. Arzneimittelforschung 1992, 42:437-445.
95. Patrucco E., Notte A., Barberis L., Selvetella G., Maffei A., Brancaccio M., et al. PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 2004, 118:375-387.
96. 3 and cAMP signaling through a PKA anchoring function of p110gamma. Mol Cell 2011, 42:84-95.
97. Marcantoni A., Levi R.C., Gallo M.P., Hirsch E., Alloatti G. Phosphoinositide 3-kinasegamma (PI3Kgamma) controls L-type calcium current (I(Ca, L)) through its positive modulation of type-3 phosphodiesterase (PDE3). J Cell Physiol 2006, 206:329-336.
98. 2-adrenergic receptor-mediated signaling. Circ Res 2006, 99:1084-1091.
99. 2+ current in rat ventricular myocytes. Br J Pharmacol 1999, 127:65-74.
100. Lehnart S.E., Wehrens X.H.T., Reiken S., Warrier S., Belevych A.E., Harvey R.D., et al. Phosphodiesterase 4D deficiency in the ryanodine receptor complex promotes heart failure and arrhythmias. Cell 2005, 123:23-35.
101. Katano Y., Endoh M. Effects of a cardiotonic quinolinone derivative Y-20487 on the isoproterenol-induced positive inotropic action and cyclic AMP accumulation in rat ventricular myocardium: comparison with rolipram, Ro 20-1724, milrinone, and isobutylmethylxanthine. J Cardiovasc Pharmacol 1992, 20:715-722.
102. Vargas M.L., Hernandez J., Kaumann A.J. Phosphodiesterase PDE3 blunts the positive inotropic and cyclic AMP enhancing effects of CGP12177 but not of noradrenaline in rat ventricle. Br J Pharmacol 2006, 147:158-163.
103. 1-adrenoceptors. Br J Pharmacol 2008, 153:710-720.
104. Katano Y., Endoh M. Differential effects of Ro 20-1724 and isobutylmethylxanthine on the basal force of contraction and beta-adrenoceptor-mediated response in the rat ventricular myocardium. Biochem Biophys Res Commun 1990, 167:123-129.
105. 1-adrenoceptors, are reduced by PDE3 in human atrium but PDE4 in CHO cells. Naunyn Schmiedebergs Arch Pharmacol 2007, 375:123-131.
106. 1-adrenoceptors in human atrial myocardium. Naunyn Schmiedebergs Arch Pharmacol 2006, 374:249-253.
107. Bolger G.B., Conti M., Houslay M.D. Cellular functions of PDE4 enzymes. Cyclic nucleotide phosphodiesterases in health and disease 2007, 99-130. CRC Press, Taylor & Francis Group, Chapter 6. S. Francis, J.A. Beavo, M.D. Houslay (Eds.).
108. Terrin A., Di Benedetto G., Pertegato V., Cheung Y.F., Baillie G., Lynch M.J., et al. PGE1 stimulation of HEK293 cells generates multiple contiguous domains with different [cAMP]: role of compartmentalized phosphodiesterases. J Cell Biol 2006, 175:441-451.
109. Leroy J., Richter W., Mika D., Castro L.R.V., Abi-Gerges A., Xie M., Scheitrum C., Lefebvre F., Schittl J., Westenbroek R., Catterall W.A., Charpentier F., Conti M., Fischmeister R., Vandecasteele G. Phosphodiesterase 4B in the cardiac L-type Ca2+ channel complex regulates Ca2+ current and protects against ventricular arrhythmias. J Clin Invest 2011, 121:2651-2661.
110. Baillie G.S., Houslay M.D. Arrestin times for compartmentalised cAMP signalling and phosphodiesterase-4 enzymes. Curr Opin Biol 2005, 17:1-6.
111. 2+-triggered membrane association with selectivity for interaction with phosphatidic acid. J Biol Chem 2002, 277:28298-28309.
112. Verde I., Pahlke G., Salanova M., Zhang G., Wang S., Coletti D., et al. Myomegalin is a novel protein of the Golgi/centrosome that interacts with a cyclic nucleotide phosphodiesterase. J Biol Chem 2001, 276:11189-11198.
113. Lugnier C., Keravis T., Le Bec A., Pauvert O., Proteau S., Rousseau E. Characterization of cyclic nucleotide phosphodiesterase isoforms associated to isolated cardiac nuclei. Biochim Biophys Acta 1999, 1472:431-446.
114. Houslay M.D., Adams D.R. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 2003, 370:1-18.
115. Carlisle Michel J.J., Dodge K.L., Wong W., Mayer N.C., Langeberg L.K., Scott J.D. PKA-phosphorylation of PDE4D3 facilitates recruitment of the mAKAP signalling complex. Biochem J 2004, 381:587-592.
116. Hoffmann R., Baillie G.S., MacKenzie S.J., Yarwood S.J., Houslay M.D. The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579. EMBO J 1999, 18:893-903.
117. 2-adrenergic receptors by β-arrestins. Science 2002, 298:834-836.
118. 2-adrenergic receptor to activation of ERK in HEK293 cells. J Biol Chem 2005, 280(39):33178-33189.
119. i. Proc Natl Acad Sci U S A 2003, 100:941-945.
120. Houslay M.D., Baillie G.S. The role of ERK2 docking and phosphorylation of PDE4 cAMP phosphodiesterase isoforms in mediating cross-talk between the cAMP and ERK signalling pathways. Biochem Soc Trans 2003, 31:1186-1190.
121. 2-adrenergic receptors is defined by differential interactions with PDE4. EMBO J 2008, 27:384-393.
122. 2-adrenoceptor in cardiac myocytes. J Biol Chem 2009, 284:33824-33832.
123. Smith C.J., Huang R., Sun D., Ricketts S., Hoegler C., Ding J.Z., et al. Development of decompensated dilated cardiomyopathy is associated with decreased gene expression and activity of the milrinone-sensitive cAMP phosphodiesterase PDE3A. Circulation 1997, 96:3116-3123.
124. Sato N., Asai K., Okumura S., Takagi G., Shannon R.P., FujitaYamaguchi Y., et al. Mechanisms of desensitization to a PDE inhibitor (Milrinone) in conscious dogs with heart failure. Am J Physiol Heart Circ Physiol 1999, 45:H1699-H1705.
125. Ding B., Abe J., Wei H., Xu H., Che W., Aizawa T., et al. A positive feedback loop of phosphodiesterase 3 (PDE3) and inducible cAMP early repressor (ICER) leads to cardiomyocyte apoptosis. Proc Natl Acad Sci U S A 2005, 102:14771-14776.
126. Ding B., Abe J., Wei H., Huang Q., Walsh R.A., Molina C.A., et al. Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure. Circulation 2005, 111:2469-2476.
127. Nagendran J., Archer S.L., Soliman D., Gurtu V., Moudgil R., Haromy A., St Aubin C., Webster L., Rebeyka I.M., Ross D.B., Light P.E., Dyck J.R., Michelakis E.D. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 2007, 116:238-248.
128. Mokni W., Keravis T., Etienne-Selloum N., Walter A., Kane M.O., Schini-Kerth V.B., et al. Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II. PLoS One 2010, 5:e14227.
129. Yan C., Miller C.L., Abe J. Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart. Circ Res 2007, 100:489-501.
130. Schroder F., Handrock R., Beuckelmann D.J., Hirt S., Hullin R., Priebe L., et al. Increased availability and open probability of single L-type calcium channels from failing compared with nonfailing human ventricle. Circulation 1998, 98:969-976.
131. 2+ channel density and regulation are altered in failing human ventricular myocytes and recover after support with mechanical assist devices. Circ Res 2002, 91:517-524.
132. Dodge-Kafka K.L., Langeberg L., Scott J.D. Compartmentation of cyclic nucleotide signaling in the heart: the role of A-kinase anchoring proteins. Circ Res 2006, 98:993-1001.
133. 2+ regulation of adenylyl cyclases in cAMP microdomains. Physiol Rev 2007, 87:965-1010.
134. Stork P.J.S., Schmitt J.M. Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol 2002, 12:258-266.
135. Osadchii O.E. Cardiac hypertrophy induced by sustained ß-adrenoreceptor activation: pathophysiological aspects. Heart Fail Rev 2007, 12:66-86.
136. Movsesian M.A. Altered cAMP-mediated signalling and its role in the pathogenesis of dilated cardiomyopathy. Cardiovasc Res 2004, 62:450-459.
137. Movsesian M.A., Bristow M.R. Alterations in cAMP-mediated signaling and their role in the pathophysiology of dilated cardiomyopathy. Curr Top Dev Biol 2005, 68:25-48.